A Single-Center, Double-Arm, Randomized Controlled Clinical Study on the Treatment of Adenomyosis with Dienogest Combined with Magnetic Resonance-Guided Focused Ultrasound Ablation

Start Date01 May 2025

Sponsor / Collaborator

Foshan Chinese Traditional Medicine Hospital

ChiCTR2500099032

/ SuspendedNot ApplicableIIT

Effect of Combined Laser and Ultrasound-Assisted Localization on First-Attempt Success Rate of Intraspinal Puncture in Elderly Patients with Hip Fractures: A Prospective, Randomized, Controlled Study

Start Date31 Mar 2025

Sponsor / Collaborator

Foshan Chinese Traditional Medicine Hospital

ChiCTR2400093708

/ SuspendedNot ApplicableIIT

A study of the current status of debilitation in elderly patients with diabetic foot and its influencing factors

Start Date01 Jan 2025

Sponsor / Collaborator

Foshan Chinese Traditional Medicine Hospital

100 Clinical Results associated with Foshan Chinese Traditional Medicine Hospital

0 Patents (Medical) associated with Foshan Chinese Traditional Medicine Hospital

787

Literatures (Medical) associated with Foshan Chinese Traditional Medicine Hospital

01 Jun 2025·Laboratory Investigation

Systematic Analysis of Factors Affecting Human Epidermal Growth Factor Receptor 2 Interpretation Consistency: Staining Protocols, Artificial Intelligence–Based Image Standardization, and Classification Criteria

Article

Author: Zheng, Chengyou ; Luo, Rongzhen ; Kong, Lingzhi ; Sun, Peng ; Wu, Yu ; Feng, Wentai ; Zhang, Jinhui ; Cai, Xi ; Xu, Shuoyu ; Jiang, Chen ; Yang, Yuanzhong ; He, Jiehua ; Chao, Xue ; Li, Mei ; Yan, Shumei

The efficacy of human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugates has underscored the critical need for precise HER2 diagnostics in breast cancer treatment. Despite the clinical importance, variability in immunohistochemical (IHC) staining protocols and interobserver inconsistencies challenge the reliability of HER2 status assessment, which is critical for guiding patient treatment strategies. To investigate the factors affecting HER2 interpretation consistency, tissue microarrays from 1063 breast carcinoma cases underwent 3 distinct IHC protocols, and a novel artificial intelligence (AI) model was developed to standardize HER2-stained images. A total of 5 sets of tissue microarrays (Nordi QC, protocol 1, protocol 2, protocol 1 AI, and protocol 2 AI) were independently reviewed by 8 pathologists. The Fleiss Kappa value and overall agreement rate measured interobserver agreement, with logistic regression analyzing the impact of variables on diagnostic accuracy. Our results showed that the Nordi QC protocol had the highest interobserver agreement (Kappa 0.754). AI-based image normalization notably enhanced consistency, particularly for HER2 low cases, aligning scores toward the Nordi QC standard. Logistic regression analysis indicated that both staining protocol and AI-based image standardization significantly influenced diagnostic accuracy (P < .001). The American Society of Clinical Oncology/College of American Pathologists 2018 binary criteria demonstrated the highest HER2 interobserver consistency (Kappa > 0.95). Compared with the American Society of Clinical Oncology/College of American Pathologists 2023 criteria, the newly proposed null, ultra-low/low, positive criteria, merging HER2 low and ultra-low categories, demonstrated improved reliability and agreement, especially in distinguishing the challenging HER2-ultra-low cases, which showed an exceedingly low interobserver agreement (Kappa < 0.20) across all protocols. Overall, variability in IHC staining protocols and HER2 classification criteria significantly affect the diagnostic consistency among pathologists. The integration of an AI model for image standardization and the adoption of the null, ultra-low/low, positive criteria may refine diagnostic precision and bolster clinical decision-making in breast cancer treatment.

01 Jun 2025·Bone

Letter to the editor concerning ‘The association of waist circumference with bone mineral density and risk of osteoporosis in US adult: National health and nutrition examination survey’

Letter

Author: Pan, Shangxian ; Yang, Kuangyang

01 Jun 2025·Injury

Based on the diamond concept, application of platelet-rich plasma in the treatment of aseptic femoral shaft nonunion: A retrospective controlled study on 66 patients

Article

Author: Wang, Shiheng ; Wu, Feng ; Jie, Ke ; Wu, Jiahua ; Chen, Jianrong ; Peng, Zhihao ; Wang, Kunyu ; Zhang, Xiuling

BACKGROUNDBiologics, particularly platelet-rich plasma (PRP), have gained attention for promoting bone healing. This study assesses the efficacy of PRP-enhanced therapy in treating aseptic femoral shaft nonunion.METHODSThis retrospective study analyzed patients who underwent femoral fracture nonunion revision surgery at a high-level trauma center between January 2021 and April 2024. Patients were divided into two groups: Group 1 (PRP-enhanced) and Group 2 (non-PRP). Group 1 received internal fixation with auxiliary plate reinforcement, PRP-enriched grafts, and bioactive center creation. The primary endpoint was bone healing rate and time to healing; secondary endpoints included lower limb function, pain scores, complications, and risk factors for nonunion at final follow-up.RESULTSSixty-six patients were included (25 in Group 1, 41 in Group 2). At final follow-up, all patients in Group 1 healed, while 80.49 % of Group 2 healed (p = 0.049). The average healing time was shorter in Group 1 (7.61 months) compared to Group 2 (11.19 months) (p < 0.001). Group 1 had superior lower limb function and pain scores (p < 0.001). Long-term smoking (OR = 9.47, 95 % CI 1.39-64.51, P = 0.022) and inappropriate post-operative weight bearing (OR = 7.62, 95 % CI 1.12-51.57, P = 0.038) were identified as risk factors for nonunion.CONCLUSIONIn nonunion revision surgery, PRP-enhanced therapy significantly improves bone healing rates, reduces healing time, and carries fewer safety risks than traditional bone grafting. It offers an effective approach for nonunion treatment and provides a standardized clinical application for PRP in fracture nonunion surgeries.

100 Deals associated with Foshan Chinese Traditional Medicine Hospital

100 Translational Medicine associated with Foshan Chinese Traditional Medicine Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Foshan Chinese Traditional Medicine Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 13 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing